Evaluation of HIV-1 resistance to antiretroviral drugs among 150 patients after six months of therapeutic interruption

Most of the antiretroviral (ARV) studies in Brazil have been reported in treatment-experienced and naive patients rather than in the setting of treatment interruption (TI). In this study, we analysed reasons given for TI and resistance mutations occurring in 150 HIV-1-infected patients who underwent TI. Of the patients analysed, 110 (73.3%) experienced TI following medical advice, while the remaining patients stopped antiretroviral therapy (ART) of their own accord. The main justifications for TI were: ARV-related toxicities (38.7%), good laboratory parameters (30%) and poor adherence (20%). DNA sequencing of the partial pol gene was successful in 137 (91.3%) patients, of whom 38 (27.7%) presented mutations conferring ARV resistance. A higher viral load prior to TI correlated with drug resistance (P < 0.05). Our results demonstrate that there are diverse rationales for TI and that detection of resistant strains during TI most likely indicates a fitter virus than the wild type. High viral loads coupled with unprotected sex in this group could increase the likelihood of transmission of drug-resistant virus. Thus, treating physicians should be alerted to this problem when the use of ARVs is interrupted.

[1]  Thomas Lengauer,et al.  Dynamics of NRTI resistance mutations during therapy interruption. , 2009, AIDS research and human retroviruses.

[2]  D. Richman,et al.  Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection , 2008, Journal of Virology.

[3]  J. Couto-Fernandez,et al.  Prevalence of HIV type 1 drug resistance mutations in treatment-naïve and experienced patients from resource-limited settings with universal access to antiretroviral therapy: a survey in two small Brazilian cities. , 2008, Memorias do Instituto Oswaldo Cruz.

[4]  Douglas D. Richman,et al.  Antiretroviral Treatment of Adult HIV Infection , 2008 .

[5]  J. Salomon,et al.  Evolution of Antiretroviral Drug Costs in Brazil in the Context of Free and Universal Access to AIDS Treatment , 2007, PLoS medicine.

[6]  M. Zazzi,et al.  Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients , 2007, Journal of Clinical Microbiology.

[7]  C. Scagnolari,et al.  Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals , 2007, Journal of acquired immune deficiency syndromes.

[8]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[9]  Matthias Cavassini,et al.  CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial , 2006, The Lancet.

[10]  S. Deeks.  The risk of treatment versus the risk of HIV replication , 2006, The Lancet.

[11]  Roger Salamon,et al.  CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial , 2006, The Lancet.

[12]  Michael P. Busch,et al.  Trends in Antiretroviral Drug Resistance and Clade Distributions Among HIV-1--Infected Blood Donors in Sao Paulo, Brazil , 2006, Journal of acquired immune deficiency syndromes.

[13]  C. Rouzioux,et al.  HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time , 2006, AIDS.

[14]  N. Saksena,et al.  Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  M. Soares,et al.  Prevalence of Human Immunodeficiency Virus Drug Resistance Mutations and Subtypes in Drug-Naive, Infected Individuals in the Army Health Service of Rio de Janeiro, Brazil , 2004, Journal of Clinical Microbiology.

[16]  J. Bartlett.  Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy , 2004 .

[17]  S. Oka,et al.  Emergence of Protease Inhibitor Resistance–Associated Mutations in Plasma HIV-1 Precedes That in Proviruses of Peripheral Blood Mononuclear Cells by More Than a Year , 2003, Journal of acquired immune deficiency syndromes.

[18]  E. Hudes,et al.  Dramatic improvement in survival among adult Brazilian AIDS patients , 2003, AIDS.

[19]  Ester C Sabino,et al.  Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals , 2003, AIDS.

[20]  G. d’Ettorre,et al.  Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing , 2003, Journal of Clinical Microbiology.

[21]  Ester C Sabino,et al.  A specific subtype C of human immunodeficiency virus type 1 circulates in Brazil , 2003, AIDS.

[22]  A. Tanuri,et al.  Prevalence of mutations related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. , 2002, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[23]  W. Bilker,et al.  Effect of adherence to newly initiated antiretroviral therapy on plasma viral load , 2001, AIDS.

[24]  F. Baldanti,et al.  Analysis of HIV drug‐resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment‐naive and HAART patients , 2001, Journal of medical virology.

[25]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[26]  C. Sabin,et al.  Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre , 2001, AIDS.

[27]  K. Hertogs,et al.  Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure , 2000, AIDS.

[28]  Robert W. Shafer,et al.  Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries , 2000, Nature Medicine.

[29]  C. Sabin,et al.  Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. , 2000, AIDS research and human retroviruses.

[30]  C. Sabin,et al.  Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients. , 2000, The Journal of infectious diseases.

[31]  C. Verhofstede,et al.  Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. , 1999, AIDS.

[32]  L. Stuyver,et al.  Sequence Diversity of the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 from Untreated Brazilian Individuals , 1999, Antimicrobial Agents and Chemotherapy.

[33]  M. Wainberg,et al.  Public health implications of antiretroviral therapy and HIV drug resistance. , 1998, JAMA.

[34]  F. Mammano,et al.  Loss of Viral Fitness Associated with Multiple Gag and Gag-Pol Processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors In Vivo , 1998, Journal of Virology.

[35]  S. Hammer,et al.  Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.

[36]  D. Lamarre,et al.  Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors , 1997, Journal of virology.

[37]  C. Loveday,et al.  The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. , 1995, AIDS research and human retroviruses.